BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 31676731)

  • 1. Head-to-Head Comparison of
    Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
    J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
    [No Abstract]   [Full Text] [Related]  

  • 2. Head-to-Head Comparison of
    Lin Z; Zhu W; Zhang J; Miao W; Yao S; Huo L
    J Nucl Med; 2023 Sep; 64(9):1406-1411. PubMed ID: 37474267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and radiation dose estimates for
    Krebs S; Pandit-Taskar N; Reidy D; Beattie BJ; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; O'Donoghue JA
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):677-685. PubMed ID: 30374529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of
    Zhu W; Jia R; Yang Q; Cheng Y; Zhao H; Bai C; Xu J; Yao S; Huo L
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1613-1622. PubMed ID: 34874478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective head-to-head comparison of
    Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of
    Krebs S; O'Donoghue JA; Biegel E; Beattie BJ; Reidy D; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; Pandit-Taskar N
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3047-3057. PubMed ID: 32378020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China.
    Liu M; Cheng Y; Bai C; Zhao H; Jia R; Chen J; Zhu W; Huo L
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2002-2011. PubMed ID: 38337073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
    Kunikowska J; Lewington V; Krolicki L
    Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Boeckxstaens L; Dekervel J; Vandamme T; Lybaert W; den Broeck BV; Laenen A; Clement PM; Geboes K; Cutsem EV; Stroobants S; Verslype C; Bormans G; Deroose CM
    J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
    [No Abstract]   [Full Text] [Related]  

  • 11. [
    Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Dekervel J; Van Cutsem E; Verslype C; Van Laere K; Bormans G; Deroose CM
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inferior performance of [
    Has Simsek D; Guzel Y; Denizmen D; Sanli Y; Buyukkaya F; Kovan B; Komek H; Isik EG; Ozkan ZG; Kuyumcu S
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):828-840. PubMed ID: 37947850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [
    Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor imaging with [
    Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of somatostatin receptor expressing tumor volume calculated from
    Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of lanreotide on uptake of
    Aalbersberg EA; de Wit-van der Veen BJ; Versleijen MWJ; Saveur LJ; Valk GD; Tesselaar MET; Stokkel MPM
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):696-703. PubMed ID: 30097670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.